A298380 Stock Overview
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
ABL Bio Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩21,900.00 |
52 Week High | ₩30,500.00 |
52 Week Low | ₩15,370.00 |
Beta | 1.08 |
1 Month Change | -13.10% |
3 Month Change | -15.44% |
1 Year Change | 6.05% |
3 Year Change | 3.06% |
5 Year Change | -27.00% |
Change since IPO | 60.44% |
Recent News & Updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26Recent updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Shareholder Returns
A298380 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -12.2% | -3.1% | 1.1% |
1Y | 6.1% | 12.6% | 3.7% |
Return vs Industry: A298380 underperformed the KR Biotechs industry which returned 12.6% over the past year.
Return vs Market: A298380 exceeded the KR Market which returned 3.7% over the past year.
Price Volatility
A298380 volatility | |
---|---|
A298380 Average Weekly Movement | 7.1% |
Biotechs Industry Average Movement | 7.7% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.2% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A298380's share price has been volatile over the past 3 months.
Volatility Over Time: A298380's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Sang Hoon Lee | www.ablbio.com |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
ABL Bio Inc. Fundamentals Summary
A298380 fundamental statistics | |
---|---|
Market cap | ₩1.05t |
Earnings (TTM) | -₩38.95b |
Revenue (TTM) | ₩33.10b |
31.7x
P/S Ratio-26.9x
P/E RatioIs A298380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A298380 income statement (TTM) | |
---|---|
Revenue | ₩33.10b |
Cost of Revenue | ₩62.83m |
Gross Profit | ₩33.04b |
Other Expenses | ₩71.99b |
Earnings | -₩38.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -813.33 |
Gross Margin | 99.81% |
Net Profit Margin | -117.67% |
Debt/Equity Ratio | 67.4% |
How did A298380 perform over the long term?
See historical performance and comparison